Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Xgeva

- PMLiVE

Roche’s Soliris rival satralizumab scores in phase 3 study

Therapy has been filed in US and Europe with decisions expected in 2020

- PMLiVE

Amgen raises forecasts after closing $13.4bn Otezla deal

Scope to build product further with ongoing trials in additional indications

- PMLiVE

Nucala works in rare inflammatory disease, says GSK

Company is planning to file for approval in indication next year

- PMLiVE

The long and winding road to asthma breakthroughs

Respiratory biologics are booming thanks to scientists who refused to be derailed by early research setbacks

China flag thumb

Amgen buys BeiGene stake for $2.7bn to aid push into China

China's oncology market forecast to nearly double in size by 2026

- PMLiVE

Amgen exits neuroscience R&D to focus on growth areas

Move has resulted in loss of around 180 jobs

- PMLiVE

GSK’s pivotal TB vaccine could prevent millions of deaths

Key study took place in TB-endemic regions, testing 3,500 participants

- PMLiVE

New hires at Amgen, Eli Lilly and Zosano

The latest movers in pharma

- PMLiVE

CHMP says OK to UCB/Amgen’s Evenity for osteoporosis after appeal

Initially received a negative opinion of the drug

- PMLiVE

Amgen reveals more data on KRAS drug

Unveiled an overall disease control rate of 100%

- PMLiVE

GSK eyes follow-up HPV vaccine

Announces new alliance with Chinese pharma Innovax

- PMLiVE

Amgen takes aim at Alexion’s patents for Soliris

Follows extension of Soliris patent protection until 2027

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links